Recent Company News

• 10:37 AM ET Nov 03, 2025
  

  Transcript Intelligence: BioNTech Q3 Earnings Guidance ($103.67, -0.24)

• 10:37 AM ET Nov 03, 2025
  

  Transcript Intelligence: BioNTech Q3 Earnings Themes ($103.67, -0.24)

• 10:36 AM ET Nov 03, 2025
  

  Transcript Intelligence: BioNTech Q3 Earnings Q&A ($103.73, -0.19)

• 09:03 AM ET Nov 03, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:27 AM ET Nov 03, 2025
  

  StreetAccount Summary - US Pre-market trading

• 06:51 AM ET Nov 03, 2025
  

  BioNTech reports Q3 net income (€28.7M) vs FactSet (€280.7M) [7 est, (€472)-(62.9M)] ($103.91, 0.00)

• 05:30 PM ET Oct 31, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 05:48 AM ET Oct 24, 2025
  

  Pfizer (PFE) and BioNTech receive Health Sciences Authority Approval for SARS-CoV-2 sublineage LP.8.1-adapted monovalent COVID-19 vaccine in Singapore ($104.75, 0.00)

• 05:33 AM ET Oct 24, 2025
  

  Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

• 06:47 AM ET Oct 22, 2025
  

  BioNTech commences public exchange offer for all outstanding shares of CureVac N.V. ($5.37, 0.00)